Inventiva Announces Resumption of Phase 3 Study for NASH Drug

Friday, 8 March 2024, 18:46

In a significant development, Inventiva's stock surged by 6% following the news of resuming screening and randomization for a Phase 3 study of its drug lanifibranor for NASH treatment. The company's decision signals positive progress in the research and potential treatment for NASH, boosting investor confidence.

https://store.livarava.com/c6a67154-dd7c-11ee-9655-5254a2021b2b.jpe — Inventiva Announces Resumption of Phase 3 Study for NASH Drug

Inventiva Resumes Phase 3 Study for NASH Drug

Inventiva's stock saw a 6% increase after the company revealed its plan to resume screening and randomization for a Phase 3 study aimed at evaluating the efficacy of lanifibranor in treating NASH.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.